Esperion Therapeutics Inc (NASDAQ:ESPR) has received an average rating of “Hold” from the sixteen research firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $75.58.

A number of equities research analysts recently weighed in on ESPR shares. Zacks Investment Research downgraded Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, February 8th. ValuEngine downgraded Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. BidaskClub raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 4th. Northland Securities reaffirmed a “buy” rating and set a $65.00 price objective on shares of Esperion Therapeutics in a research report on Friday, March 1st. Finally, JPMorgan Chase & Co. raised Esperion Therapeutics from an “underweight” rating to a “neutral” rating and raised their price objective for the company from $38.00 to $47.00 in a research report on Wednesday, March 13th.

In other Esperion Therapeutics news, CEO Timothy M. Mayleben purchased 5,000 shares of the stock in a transaction on Thursday, March 14th. The stock was acquired at an average price of $48.73 per share, with a total value of $243,650.00. Following the completion of the acquisition, the chief executive officer now owns 51,163 shares in the company, valued at $2,493,172.99. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Target N. V. Biotech purchased 50,000 shares of the stock in a transaction on Thursday, March 14th. The stock was acquired at an average cost of $49.89 per share, with a total value of $2,494,500.00. Following the acquisition, the insider now owns 3,522,964 shares of the company’s stock, valued at approximately $175,760,673.96. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 65,000 shares of company stock worth $3,155,550 and have sold 48,329 shares worth $2,280,206. 14.50% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Creative Planning raised its stake in shares of Esperion Therapeutics by 3.8% in the fourth quarter. Creative Planning now owns 7,849 shares of the biopharmaceutical company’s stock worth $361,000 after purchasing an additional 287 shares during the last quarter. Advisor Group Inc. raised its stake in shares of Esperion Therapeutics by 44.4% in the fourth quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 291 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of Esperion Therapeutics by 7.0% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 11,100 shares of the biopharmaceutical company’s stock worth $511,000 after purchasing an additional 729 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Esperion Therapeutics by 2.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 42,400 shares of the biopharmaceutical company’s stock worth $1,950,000 after purchasing an additional 950 shares during the last quarter. Finally, Rehmann Capital Advisory Group purchased a new position in shares of Esperion Therapeutics in the fourth quarter worth about $97,000.

Shares of Esperion Therapeutics stock opened at $41.91 on Monday. The firm has a market cap of $1.17 billion, a PE ratio of -5.56 and a beta of 2.13. Esperion Therapeutics has a 12 month low of $33.06 and a 12 month high of $73.33.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.24) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.94). As a group, analysts forecast that Esperion Therapeutics will post -2.93 EPS for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Further Reading: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.